Search

Your search keyword '"Parquet, Nathalie"' showing total 232 results

Search Constraints

Start Over You searched for: Author "Parquet, Nathalie" Remove constraint Author: "Parquet, Nathalie"
232 results on '"Parquet, Nathalie"'

Search Results

1. Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification

2. Clinical features and genomic landscape of myeloproliferative neoplasm (MPN) patients with autoimmune and inflammatory diseases (AID)

3. Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life study

4. Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma

5. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia

6. Extracorporeal Membrane Oxygenation (ECMO) during aplasia: a bridge towards myopericarditis recovery after autologous Hematopoietic Stem Cell Transplant for Systemic Sclerosis and recent Coronarovirus Disease (COVID-19) vaccination

9. Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification

10. Management of erythropoietic protoporphyria with cholestatic liver disease: A case report

11. Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC‐PM.

13. Clinical Features and Genomic Landscape of Myeloproliferative Neoplasm (MPN) Patients with Autoimmune and Inflammatory Diseases (AID)

14. CD24hiCD27+ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease

15. Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life study

16. Prognosis of Hyperviscosity Syndrome in Newly Diagnosed Multiple Myeloma in Modern-Era Therapy: A Real-Life Monocentric Study

17. JAK Inhibition Mediates Clonal Selection of RAS Pathway Mutations in Myeloproliferative Neoplasms

18. Distinct Clinico-Molecular Arterial and Venous Thrombotic Scoring Systems for MPN Patients Risk Stratification

19. Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim

22. Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma

25. Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modernera therapy: A real-life study.

26. Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms

27. Chronic Exposure to Cytoreductive Treatment Shapes Clonal Evolution in Myeloproliferative Neoplasms

28. Genomic Landscape and Clinical Features of Myeloproliferative Neoplasm (MPN) Patients with Auto-Immune and Inflammatory Diseases (AID)

29. Myeloproliferative Neoplasms (MPN) Clonal Evolution Landscape and Its Impact on Patients' Prognosis

30. Expansion of Circulating CD49b+LAG3+ Type 1 Regulatory T Cells in Human Chronic Graft-Versus-Host Disease

31. Unresponsive thrombotic thrombocytopenic purpura in critically ill adults

33. Failure and out of Specification Manufacturing of Autologous CAR-T Cells Could be Associated with a High Concentration of Total Nucleated Cells, CD3 + Cells and Neutrophils in the Apheresis Product

34. Low Disease Burden Pre-CAR-T Cell Therapy for Children and AYA with B-ALL Is Associated with an Impaired Outcome When Obtained through Intensification of the Bridging Therapy

35. Anemia and hemodilution: analysis of a single center cohort based on 2,858 red cell mass measurements

36. Outcomes 18 months after the first human partial face transplantation

38. Quality risk management of the chimeric antigen receptor T cell pharmaceutical circuit in one of the first qualified European centers

39. SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)

40. NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN)

41. Ruxolitinib Treatment Is Associated with Increased Incidence of Infections and Higher Risk of HSV/Vzv Recurrence in Patients with Myeloproliferative Neoplasm (MPN) Related Myelofibrosis (MF)

42. Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission

43. FIRST FACE ALLOGRAFT: A THREE YEARS FOLLOW UP: O-277

45. Safety of CD34+ Hematopoietic Stem Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46 in HIV-1 Infected Patients with High-Risk Lymphoma

46. Safety and Efficacy of Tisagenlecleucel (CTL019) in B-Cell Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults: The French Experience

Catalog

Books, media, physical & digital resources